Antimicrobial agents—including antibiotics, antifungals, and antivirals—constitute a fundamental pillar of modern medicine, routinely administered worldwide to manage life-threatening infectious diseases. However, the sustained clinical efficacy of these therapies is increasingly imperiled by two interconnected global health crises: the accelerated emergence of antimicrobial resistance (AMR) and extensive interindividual variability in pharmacological response1. Optimal antimicrobial dosing is designed to maintain free drug concentrations at the target site of infection above the pathogen's minimum inhibitory concentration (MIC) for an adequate exposure duration, thereby maximizing microbial clearance and suppressing the emergence of resistant subpopulations. The governing pharmacokinetic/pharmacodynamic (PK/PD) index—whether time above MIC (fT > MIC), the peak concentration-to-MIC ratio (C_max/MIC), or the area under the concentration–time curve-to-MIC ratio (AUC/MIC)—is intrinsically class-dependent2. Unrecognized alterations in fundamental pharmacokinetic parameters, particularly metabolic clearance and systemic elimination, frequently disrupt this fragile equilibrium. Such deviations result in either subtherapeutic drug exposure, which fuels treatment failure and secondary resistance selection, or supratherapeutic accumulation, precipitating severe concentration-dependent toxicity and adverse drug reactions (ADRs)3.

A primary determinant of interindividual pharmacokinetic variability is the superordinate superfamily of hemoprotein monooxygenases designated cytochrome P450 (CYP450)4. These heme-dependent oxidoreductases represent the central catalytic machinery of hepatic Phase I biotransformation, displaying their highest expression levels within hepatocytes and enterocytes5. CYP enzymes mediate the metabolic processing of numerous endogenous biochemical substrates—including steroid hormones, bile acids, fat-soluble vitamins, and procarcinogens—while simultaneously processing xenobiotic entities, accounting for the oxidative metabolism of approximately 75% of clinically prescribed pharmaceutical agents6. Mechanistically, these enzymes catalyze the insertion of a single atom of molecular oxygen into lipophilic drug substrates (principally via mono-hydroxylation, dealkylation, or epoxidation), thereby generating polar functional handles that facilitate subsequent Phase II conjugation (e.g., glucuronidation, sulfation, or glutathione conjugation) and ultimate excretion via renal or hepatobiliary pathways7. Consequently, CYP-mediated biotransformation serves as the primary gateway for the detoxification and systemic clearance of numerous lipophilic antimicrobials8.

Crucially, this Phase I-to-Phase II handoff is not invariably cytoprotective. Certain CYP-catalyzed oxidative transformations generate highly reactive, electrophilic intermediates (e.g., reactive epoxides, quinone imines, and N-hydroxylamines) at rates exceeding the quenching capacity of downstream Phase II transferases (such as glutathione S-transferases and UDP-glucuronosyltransferases). Under conditions of phenoconversion—wherein a functional metabolic bottleneck is created through competitive inhibition, allosteric disruption, or accelerated oxidative flux—these electrophilic intermediates can accumulate intracellularly, exhaust hepatic glutathione reserves, and covalently adduct critical cellular macromolecules. This cascade induces mitochondrial collapse, severe oxidative stress, and catastrophic idiosyncratic or dose-dependent hepatotoxicity. This biochemical vulnerability explains why dynamic phenoconversion, rather than germline genotype alone, frequently precipitates the acute hepatic adverse events observed with CYP-cleared antimicrobial therapies.

The genes encoding clinically relevant CYP isoforms exhibit profound genetic polymorphism, harboring extensive allelic diversity that includes single nucleotide polymorphisms (SNPs), copy number variations (CNVs; gene deletions and duplications), and rare uncharacterized structural variants9. These inherited genetic lesions represent a substantial, predictable, yet frequently neglected source of interindividual pharmacokinetic variability. A patient's inherited allelic architecture defines their baseline metabolic phenotype (traditionally classified into poor, intermediate, normal/extensive, and ultra-rapid metabolizers), dictating systemic clearance and biological exposure to both the parent compound and its active or toxic metabolites10. Consequently, uniform standard dosing regimens that fail to account for baseline pharmacogenetic variance frequently prove clinically ineffective or excessively toxic, presenting a formidable obstacle to precision antimicrobial therapeutics11.

Inpatient antimicrobial regimens exhibit heightened vulnerability to both pharmacogenetic heterogeneity and complex drug–drug interactions (DDIs). Because several antimicrobials act as potent inhibitors (e.g., macrolides, azoles) or inducers (e.g., rifamycins) of CYP enzymes, a baseline gene–drug interaction (GDI) frequently converges with a concurrent DDI to produce a synergistic gene–drug–drug interaction (GDDI)12. Critically ill patients are almost universally subjected to complex polypharmacy regimens—often receiving concurrent anticoagulants, cardiovascular agents, psychotropics, and immunosuppressants—rendering them acutely vulnerable to these synergistic interactions. Because a patient's underlying genetic profile determines the absolute clinical magnitude of a DDI, elucidating these intersecting mechanisms is essential for engineering proactive dosing strategies that protect therapeutic efficacy and patient safety in high-acuity clinical environments, as illustrated in the conceptual workflow of Figure 113.

This narrative review synthesizes contemporary biomedical evidence retrieved through structured literature queries across PubMed/MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library for peer-reviewed studies published between January 2015 and 2026, with prioritized focus on investigations published from 2020 onward. Search syntax utilized Boolean combinations of relevant MeSH terms and keywords, including: ("Cytochrome P450" OR "CYP450" OR "CYP2C19" OR "CYP3A4" OR "CYP2D6" OR "CYP2C9") AND ("pharmacogenomics" OR "pharmacogenetics" OR "phenoconversion" OR "gene-drug interaction" OR "drug-drug interaction") AND ("antimicrobial" OR "antibiotic" OR "antifungal" OR "voriconazole" OR "clarithromycin" OR "rifampin" OR "linezolid"). Manual cross-referencing of bibliographies from retrieved articles and clinical consensus statements (e.g., Clinical Pharmacogenetics Implementation Consortium [CPIC] and Dutch Pharmacogenetics Working Group [DPWG]) identified additional relevant sources. Methodological priority was accorded to systematic reviews, meta-analyses, consensus pharmacogenomic guidelines, and prospective pharmacokinetic/pharmacodynamic clinical trials; case reports and narrative reviews were cited selectively to elucidate rare or emerging toxicological mechanisms. In accordance with SANRA (Scale for the Assessment of Narrative Review Articles) quality guidelines, this review presents explicit therapeutic aims, describes comprehensive search parameters, maintains rigorous citation of primary literature throughout, and integrates structured analytical evidence within the accompanying table and figure.

Cytochrome P450 enzymes derive their name from their characteristic spectrophotometric absorption maximum at 450 nm when their reduced heme iron is complexed with carbon monoxide. Structurally, CYP450 enzymes are membrane-bound, b-type heme-containing monooxygenases located primarily within the endoplasmic reticulum and inner mitochondrial membrane. During their catalytic cycle, they activate molecular dioxygen, inserting one oxygen atom into the lipophilic substrate and reducing the second atom to water14. This catalytic cascade is sustained by electron transfer from reduced nicotinamide adenine dinucleotide phosphate (NADPH) via the flavoprotein NADPH-cytochrome P450 oxidoreductase (POR)15. CYP enzymes feature remarkably malleable substrate-binding pockets, enabling the stereospecific biotransformation of structurally disparate molecules, including xenobiotics, steroid hormones, vitamins, and procarcinogens15. This oxidative flexibility is essential for converting hydrophobic antimicrobial agents into hydrophilic derivatives amenable to excretion16.

The human CYP superfamily is classified into evolutionary families and subfamilies based on amino acid sequence homology (designated by family number, subfamily letter, and individual gene number; e.g., CYP3A4). Xenobiotic and drug biotransformation is predominantly mediated by enzymes belonging to the CYP1, CYP2, and CYP3 families17.

CYP3A4: Quantitatively the most abundant CYP enzyme in both the adult human liver (~30% of total hepatic CYP content) and intestinal epithelium (~70% of mucosal CYP content), CYP3A4 is responsible for metabolizing approximately 50% of all clinically prescribed therapeutic drugs18. Its vast, flexible active site accommodates structurally diverse substrates, rendering it extraordinarily susceptible to both competitive and mechanism-based drug interactions across multiple antimicrobial classes18.

CYP2D6: Although accounting for only 2% to 4% of total hepatic CYP protein content, CYP2D6 metabolizes 20% to 25% of clinically used medications, including extensive arrays of antidepressants, antipsychotics, antiarrhythmics, and beta-blockers. Uniquely among the primary drug-metabolizing CYPs, CYP2D6 is virtually non-inducible by xenobiotics, meaning its clinical variability is predominantly governed by extensive inherited polymorphism and competitive pharmacological inhibition19.

CYP2C Subfamilies (CYP2C9 and CYP2C19): Constituting approximately 20% of hepatic CYP content, the CYP2C subfamily mediates the biotransformation of numerous clinically essential drugs with narrow therapeutic windows across cardiology, neurology, and infectious diseases20. CYP2C9 clears agents such as warfarin, phenytoin, and sulfamethoxazole, whereas CYP2C19 is the principal enzyme governing the metabolic clearance of the triazole antifungal voriconazole, proton pump inhibitors, and the antiplatelet prodrug clopidogrel20.

Phase I functionalization reactions catalyzed by CYP monooxygenases introduce or unmask polar functional groups (-OH, -NH₂, -SH, or -COOH), modifying substrate physicochemical properties and preparing the molecule for Phase II synthetic conjugation21. Depending on the intrinsic chemical structure of the xenobiotic and the specific metabolic pathway involved, CYP biotransformation produces two opposing pharmacological outcomes:

Detoxification: The primary and most favorable pathway, whereby a biologically active, lipophilic antimicrobial agent is converted into an inactive, more polar, and readily excretable metabolite22.

Bioactivation: The enzymatic conversion of an inactive or weakly active parent drug (a prodrug) into its therapeutically active form, or alternatively, the conversion of a benign parent compound into a chemically reactive, electrophilic, or cytotoxic metabolite23.

Because CYP enzymes are concentrated within hepatic parenchyma, altered metabolic capacity directly influences liver homeostasis. When genetically impaired enzyme clearance (poor metabolizer status) or potent co-medication-induced enzymatic inhibition halts primary detoxification pathways, systemic parent drug concentrations escalate dramatically. Concurrently, if metabolic shunting into minor secondary oxidative pathways generates reactive metabolites, the risk of severe, idiosyncratic, or dose-dependent hepatotoxicity increases substantially24,25.

Inherited functional variability across the CYP superfamily arises from diverse genomic alterations. Single nucleotide polymorphisms (SNPs) are the most frequent variations, involving single-base substitutions within coding exons, promoter/enhancer elements, intron-exon splice junctions, or untranslated regions (UTRs)26. SNPs can diminish enzymatic activity by disrupting substrate binding, altering protein folding, causing premature transcriptional termination, or creating aberrant mRNA splice variants. Concurrently, copy number variations (CNVs)—encompassing complete whole-gene deletions, duplications, or higher-order multiduplications—exert major structural effects27. In the case of CYP2D6, CNVs range from whole-gene deletions (e.g., the non-functional CYP2D6*5 allele) to multi-copy gene duplications (e.g., CYP2D6*1xN, *2xN), which generate the ultra-rapid metabolizer phenotype28. Less frequent genetic lesions, such as insertions, deletions (indels), and variable number tandem repeats (VNTRs), further expand this functional heterogeneity, underscoring the necessity of comprehensive genomic profiling to accurately predict individual drug clearance29.

The population distribution of CYP variant alleles is marked by pronounced geospatial and ancestral stratification. A prominent example is the distribution of loss-of-function alleles in CYP2C19 (primarily *2 and *3): the prevalence of the poor metabolizer phenotype reaches 13% to 23% in East Asian populations, compared to merely 2% to 5% in European (Caucasian) cohorts30. This substantial genetic divergence has direct clinical ramifications for antimicrobials with narrow therapeutic indices that rely heavily on CYP2C19 clearance, most notably the antifungal voriconazole31. The persistence of ancestral divergence highlights a critical blind spot in the current biomedical evidence base, which remains heavily derived from single-ancestry cohorts of European descent. Extrapolating dosing guidelines established in low-prevalence populations to high-prevalence ancestral groups can lead to under-recognition of poor metabolizers, precipitating severe toxicity. Conversely, failing to recognize high-frequency ultra-rapid alleles in other cohorts promotes subtherapeutic dosing and microbiological failure. Resolving these disparities necessitates the conduct of multi-ethnic prospective pharmacogenomic trials that capture diverse global populations32.

Clinical pharmacogenomics translates an individual's inherited diplotype into an assigned activity score and predicted metabolic phenotype to guide personalized pharmacotherapy:

Normal Metabolizers (NMs) / Extensive Metabolizers (EMs): Individuals possessing two fully functional wild-type alleles (activity score typically 2.0), displaying standard baseline clearance and expected therapeutic drug exposure33.

Intermediate Metabolizers (IMs): Individuals carrying one fully functional allele paired with a reduced-function or non-functional allele, or two reduced-function alleles (activity score typically 0.5–1.0), resulting in decreased clearance capacity34.

Poor Metabolizers (PMs): Individuals homozygous or compound heterozygous for loss-of-function alleles (activity score 0), exhibiting severely compromised or absent enzymatic clearance. For active drugs, this deficiency causes systemic drug accumulation and heightened risk of concentration-dependent toxicity; for prodrugs, it precludes adequate generation of the therapeutic moiety, culminating in clinical failure35.

Ultra-Rapid Metabolizers (UMs): Individuals carrying duplicated or multiplied functional alleles (activity score >2.0) or specific promoter gain-of-function variants (e.g., CYP2C19*17), conferring markedly elevated metabolic clearance. For active drugs, ultra-rapid clearance leads to subtherapeutic systemic concentrations and therapeutic failure; for prodrugs, accelerated biotransformation causes rapid accumulation of active metabolites and heightened toxicity6.

This fundamental divergence—wherein the same metabolizer phenotype produces opposite clinical consequences depending on whether the parent drug is an active moiety or an inactive prodrug—is designated the "substrate paradox"36. Recognizing this paradox is essential for clinical decision-making, as the appropriate therapeutic adjustment (dose reduction versus dose escalation, or drug substitution) must be inverted based on the drug's metabolic activation requirements. The clinical consequences of these phenotypes are summarized in Table 1 (located after the References section)12,34,37,38.

Substrates: The antimicrobial molecule relies on CYP-mediated oxidation for its systemic clearance (e.g., voriconazole clearance by CYP2C19 and CYP3A4). In this context, the patient's germline genotype directly dictates antimicrobial elimination rates and half-life40,41.

Inhibitors: The antimicrobial impairs the catalytic activity of specific CYP isoforms through competitive, non-competitive, or mechanism-based inactivation, reducing the clearance of co-administered substrates and elevating their systemic exposure42.

Inducers: The antimicrobial upregulates CYP gene transcription via nuclear receptor pathways, accelerating the clearance of co-administered substrates and predisposing to therapeutic failure43.

Genetic variability in CYP450 enzymes directly compromises antimicrobial efficacy. When an active antimicrobial substrate is administered to an ultra-rapid metabolizer (UM), accelerated metabolic clearance prevents systemic and tissue concentrations from achieving or maintaining the target PK/PD threshold (e.g., fT > MIC or AUC/MIC), leading to persistent infection and clinical treatment failure30. Conversely, when a prodrug is prescribed to a poor metabolizer (PM), impaired bioactivation restricts active metabolite formation below the threshold required for antimicrobial efficacy60.

Beyond individual treatment failure, this pharmacokinetic shortfall has profound public health implications. Exposing pathogens to subtherapeutic antimicrobial concentrations creates an ideal selective environment for the de novo emergence and enrichment of drug-resistant mutants. Subtherapeutic exposure substantially accelerates the evolution and dissemination of antimicrobial resistance globally. Consequently, optimizing antimicrobial dosing via pharmacogenomic principles represents not only an individualized patient-safety measure, but a critical public health strategy to curb AMR selection61.

The most acute clinical hazard of CYP polymorphism is concentration-dependent toxicity in poor metabolizers. When active antimicrobials are cleared slowly (e.g., voriconazole accumulation in CYP2C19 PMs), supratherapeutic drug accumulation predictably triggers severe adverse reactions62. These toxicities encompass life-threatening neurotoxicity (encephalopathy, visual hallucinations), severe drug-induced liver injury (cholestatic or hepatocellular damage), and cardiac electrophysiological disturbances (QTc prolongation predisposing to torsades de pointes)63. Conversely, for prodrugs, ultra-rapid metabolizers face heightened toxicity risks due to the rapid, unregulated generation of active or reactive metabolites. Furthermore, this risk is dramatically amplified when co-medications trigger phenoconversion (shifting a genotypic EM to a functional PM) in multimorbid patients receiving polypharmacy64.

Applying adult pharmacogenomic data directly to pediatric populations is confounded by enzyme ontogeny—the developmental maturation of metabolic enzymes from gestation through adolescence. The hepatic expression and catalytic activity of major CYP enzymes are immature at birth, particularly in preterm neonates and young infants65. Consequently, young infants often function as phenotypic poor metabolizers regardless of their inherited germline genotype, requiring conservative weight-based dosing66. As children mature, these enzymes undergo rapid developmental upregulation, establishing the inherited genotype as a permanent determinant of drug clearance. Because pediatric patients frequently receive higher weight-adjusted doses (mg/kg) and undergo rapid developmental transitions, unrecognized poor or ultra-rapid phenotypes can cause severe toxicity or rapid treatment failure, providing a compelling rationale for preemptive pharmacogenomic testing in pediatric specialty care66,67.

Enzyme ontogeny follows isoform-specific maturation curves that further complicate pediatric dosing. CYP3A4 activity is low at birth (~30%–40% of adult levels), rises rapidly over the first months of life, and achieves adult-equivalent activity by 6 to 12 months, with some cohorts demonstrating a transient childhood overshoot exceeding adult clearance before stabilizing post-puberty. In contrast, CYP2C19 matures more slowly: neonatal activity is minimal, increases gradually during infancy, and does not reliably achieve adult functional capacity until 1 to 5 years of age. Thus, a genotypic CYP2C19 normal metabolizer may clinically behave as a functional poor metabolizer throughout early infancy. These divergent developmental timelines preclude uniform pediatric dose-extrapolation rules, necessitating age- and isoform-specific dosing frameworks.

Hospitalized patients, particularly those admitted to intensive care units (ICUs), are uniquely vulnerable to adverse outcomes driven by CYP variability. Critically ill individuals frequently present with dynamic organ dysfunction (acute kidney injury, hepatic congestion), altered capillary permeability, hypoalbuminemia, and massive polypharmacy68. The concurrent administration of multiple enzyme inhibitors or inducers substantially increases the incidence of drug-induced phenoconversion. For instance, when an ICU patient concurrently receives a potent CYP2D6 inhibitor and a strong CYP3A4 inhibitor (e.g., clarithromycin), an extensive multi-pathway metabolic blockade is established. In this environment, dynamic phenoconversion represents an immediate clinical threat that eclipses the static genotype. Conversely, while ambulatory outpatients experience lower rates of polypharmacy, they are monitored less frequently with laboratory testing; unrecognized poor metabolizer status can silently culminate in serious, unmonitored toxicities before clinical detection occurs69.

Technological innovations over the past decade have dramatically improved the analytical speed, accuracy, and affordability of pharmacogenomic (PGx) testing. Contemporary platforms—ranging from targeted TaqMan allelic discrimination assays and digital droplet PCR to multiplexed mass spectrometry arrays and next-generation sequencing (NGS) panels—interrogate the full spectrum of clinically annotated CYP variants, including SNPs, indels, and CNVs across CYP2D6, CYP2C19, CYP2C9, and CYP3A470. Although these platforms deliver high analytic fidelity in defining germline diplotypes, translating a static laboratory genotype into a real-time, actionable bedside phenotype in a patient receiving multiple interacting medications remains a substantial clinical challenge71.

Bridging the gap between raw genomic data and bedside prescribing requires automated Clinical Decision Support Systems (CDSS) embedded within Electronic Health Record (EHR) platforms. Modern CDSS tools cross-reference inherited genotype data against pharmacogenomic guidelines (e.g., CPIC, DPWG), delivering interruptive alerts and tailored dosing recommendations directly into the physician's ordering interface72. However, conventional first-generation CDSS platforms are fundamentally limited: they analyze gene–drug interactions in isolation, failing to account for multi-drug regimens or dynamic phenoconversion. Next-generation clinical algorithms must incorporate real-time medication administration records, drug–drug interaction engines, and fluctuating physiological variables (e.g., systemic inflammation, renal/hepatic clearance markers) to compute a patient's true "dynamic phenotype" at the bedside35.

Despite substantial clinical promise, widespread clinical adoption of preemptive PGx testing faces persistent economic and logistical barriers. Although sequencing chemistry costs have dropped, the institutional investment required to establish, validate, and maintain clinical-grade informatics infrastructure and train healthcare providers remains significant73. Outside of high-evidence exemplars such as voriconazole/CYP2C19, health-economic models demonstrate mixed cost-effectiveness across general antimicrobial prescribing, often secondary to variable test turnaround times and discordant guideline recommendations74. Furthermore, inequities in testing access persist: advanced PGx infrastructure is disproportionately concentrated in tertiary academic medical centers, raising global health-equity concerns regarding access for rural and underserved patient populations75.

To realize the full clinical promise of precision antimicrobial therapeutics, validated pharmacogenomic recommendations must be formally codified within institutional and international clinical practice guidelines. Currently, clinical guidelines with definitive, actionable dosing recommendations are restricted to a select group of established antimicrobial agents (e.g., CPIC and DPWG guidelines for voriconazole based on CYP2C19 genotype)76. Guidelines should mandate preemptive testing for narrow-therapeutic-index substrates in high-risk populations (PMs and UMs) to guide dose adjustments or prompt substitution with alternative non-CYP-cleared antimicrobials. Transitioning from reactive genotyping (ordered only after treatment failure or toxicity manifests) to preemptive multi-gene screening before therapy initiation is essential to optimize clinical outcomes77.

Antimicrobial Stewardship Programs (ASPs) are established hospital structures tasked with optimizing antimicrobial selection, dosing, and duration to improve clinical cure rates, minimize toxicity, and curb the emergence of antimicrobial resistance. Integrating pharmacogenomic (PGx) stewardship into established ASP workflows represents a powerful synergy78. PGx-informed stewardship teams—comprising infectious disease physicians, clinical pharmacologists, and clinical pharmacists—can proactively screen high-risk antimicrobial orders, evaluate intersecting drug–gene and drug–drug interactions, and recommend personalized dosing regimens prior to therapy initiation79.

Managing the computational complexity of polypharmacy, physiological fluctuations, and intersecting GDDIs necessitates advanced analytic tools. Model-informed precision dosing (MIPD) platforms increasingly utilize artificial intelligence (AI) and machine learning (ML) architectures80. Machine learning models can synthesize high-dimensional clinical datasets, integrating an individual's static CYP450 genotype, dynamic hepatic/renal function biomarkers, real-time co-medication profiles, and therapeutic drug monitoring (TDM) levels81. This capability allows AI systems to transcend rigid rules-based alerts, dynamically predicting individual drug clearance trajectories and the net impact of competing inhibition and induction pathways. This computational integration establishes a foundation for adaptive, predictive dosing regimens that simultaneously prevent concentration-dependent toxicity and treatment failure82.

The clinical principles of CYP-mediated pharmacokinetics extend directly into advanced therapy medicinal products (ATMPs) and cellular therapeutics. Recipients of chimeric antigen receptor (CAR) T-cell therapy, allogeneic hematopoietic stem cell transplantation (HSCT), and solid organ transplantation are maintained on long-term immunosuppressive regimens (calcineurin inhibitors such as tacrolimus and cyclosporine; mTOR inhibitors such as sirolimus), which are narrow-therapeutic-index CYP3A4 substrates. Concurrently, profound immunosuppression renders these patients highly susceptible to opportunistic bacterial and fungal infections, necessitating intensive prophylaxis with CYP3A4-interacting antimicrobials and antifungals (e.g., voriconazole, posaconazole, clarithromycin). This convergence creates severe GDDI risks: for example, co-administering voriconazole with tacrolimus can increase tacrolimus trough concentrations several-fold via potent CYP3A4 inhibition, necessitating empirical 60% to 75% tacrolimus dose reductions and intensive TDM to prevent acute nephrotoxicity and neurotoxicity. While engineered cellular products are not themselves CYP substrates, their supportive pharmacotherapy is tightly linked to CYP450 metabolism. Incorporating CYP pharmacogenomics and phenoconversion surveillance into clinical oncology and cellular therapy pathways represents an essential frontier for precision antimicrobial management.

Although the clinical utility of pharmacogenomics is firmly established for select antimicrobials such as voriconazole, robust clinical endpoint evidence (mortality reduction, shortened hospital stay, resistance mitigation) remains sparse for many commonly used antibacterial agents. Furthermore, static germline testing fails to capture the dynamic reality of in vivo drug metabolism: fluctuating co-medications, evolving systemic inflammation, organ failure, and environmental factors can rapidly alter metabolic phenotype over time. Reconciling static genetic data with dynamic clinical changes requires the seamless integration of preemptive genotyping, continuous TDM, and responsive decision-support algorithms.

The future of precision antimicrobial dosing lies in integrating pharmacogenomics with multi-omics profiling. Combining genomics with quantitative proteomics, metabolomics, and epigenomics provides an integrated assessment of an individual's real-time metabolic capacity77,78,83,86. In particular, targeted quantitative proteomics (e.g., liquid chromatography–tandem mass spectrometry [LC-MS/MS]) can directly measure hepatic and intestinal CYP protein abundance, identifying discrepancies between genotype-predicted activity and actual functional enzyme expression during critical illness or severe inflammation79,85. Advanced AI architectures are uniquely equipped to process this multi-dimensional data—combining germline genomic risk, targeted proteomic quantification, real-time clinical variables, and TDM feedback—to generate high-fidelity, adaptive pharmacokinetic forecasts that facilitate preemptive, truly individualized antimicrobial therapy80,81,84,86,87.

Two translational avenues warrant particular development. First, quantitative targeted proteomics enables direct measurement of functional CYP3A4, CYP2C19, and CYP2D6 protein abundance, correcting for phenotypic divergence driven by inflammation or acute liver injury85. Second, next-generation model-informed precision dosing (MIPD) platforms, combining population pharmacokinetic models with Bayesian forecasting and machine-learning refinement, can assimilate these multi-omics inputs to compute continuous, individualized dosing trajectories80,81,84,86,87. For narrow-therapeutic-index antimicrobials, coupling genotype with proteomic profiling and Bayesian MIPD algorithms provides a clear translational pathway from static guidelines to individualized bedside precision dosing.